We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




Mutation Identified That Reduces Type II Diabetes Risk

By LabMedica International staff writers
Posted on 12 May 2015
Print article
HumanExome BeadChip v1.2
HumanExome BeadChip v1.2 (Photo courtesy of Illumina)
A mutation in the GLP1R (glucagon-like peptide 1 receptor) gene was found to reduce the risk of developing Type II diabetes by nearly 14%.

The protein encoded by the chromosome six GLP1R gene is a member of the glucagon receptor family of G protein-coupled receptors. GLP1R binds specifically to glucagon-like peptide-1 (GLP1) and has much lower affinity for related peptides such as the gastric inhibitory polypeptide and glucagon. GLP1R is known to be expressed in pancreatic beta cells where it stimulates the adenylyl cyclase pathway, which results in increased insulin synthesis and release of insulin. GLP1R is also expressed in the brain where it is involved in the control of appetite.

Investigators at Cedars-Sinai Medical Center (Los Angeles, CA, USA) and colleagues in the Cohorts for Heart and Aging Research in Genomic Epidemiology international consortium used Illumina (San Diego, CA, USA) HumanExome BeadChip technology to analyze the genes of 81,000 people who did not have Type II diabetes and then compared their genetic information to that of 16,000 diabetics.

The HumanExome BeadChip covers functional exonic variants selected from over 12,000 individual exome and whole-genome sequences. The exonic content consists of more than 240,000 markers representing diverse populations, including European, African, Chinese, and Hispanic individuals, and a range of common conditions, such as Type II diabetes, cancer, metabolic, and psychiatric disorders.

Results of the exome mapping study were published in the January 29, 2015, online edition of the journal Nature Communications. They revealed that a mutation in the GLP1R gene appeared to decrease the risk of developing Type II diabetes by about 14%.

Senior author Dr. Mark O. Goodarzi, professor of endocrinology at Cedars-Sinai Medical Center, said, "We have a wonderful opportunity to personalize the treatment and prevention of this chronic disease. Identification of genes that influence the risk of diabetes is going to open new frontiers in diabetes drug development. The mutation we discovered may prevent certain people from developing diabetes, but it does not appear to affect their risk of becoming obese or their body mass index."

Related Links:

Cedars-Sinai Medical Center
Illumina


Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








BIOHIT  Healthcare OY

Channels

Industry News

view channel
Image: Randox and Bosch Healthcare Collaboratively Combat COVID-19 with Game-Changing Partnership (Photo courtesy of Randox Laboratories)

Randox and Bosch Healthcare Collaboratively Combat COVID-19 with Game-Changing Partnership

The game-changing partnership between Randox Laboratories (Crumlin, UK) and Bosch Healthcare (Waiblingen, Germany) continues to alter the testing landscape and capabilities of both laboratory and non-laboratory... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.